A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients

Trial Profile

A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Renal cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 29 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 21 Nov 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017.
    • 13 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top